Sanofi ADR (SNY) - Stock Price & Dividends

Exchange: USA Stocks • Country: France • Currency: USD • Type: Common Stock • ISIN: US80105N1054

Sanofi ADR (NASDAQ: SNY) is a global healthcare company that focuses on researching, developing, manufacturing, and marketing therapeutic solutions worldwide. With operations spanning the United States, Europe, and other regions, Sanofi operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments.

The company offers specialty care in areas such as neurology, rare diseases, oncology, and rare blood disorders, as well as medicines for diabetes and cardiovascular diseases. Sanofi also provides a range of pediatric vaccines like polio, pertussis, and Hib, along with influenza, booster, and meningitis vaccines, among others.

In the consumer healthcare space, Sanofi produces cough, cold, and flu remedies, allergy products, pain relief solutions, and wellness products for physical, mental, and digestive well-being. Their product line includes body lotions, anti-itch treatments, moisturizing creams, and eczema powders, catering to diverse consumer needs.

Apart from its core offerings, Sanofi collaborates with industry partners to develop innovative solutions. Working with companies like Exscientia, ABL Bio, Blackstone Life Sciences, and Seagen Inc., Sanofi is committed to advancing research in areas like oncology, immunology, and Parkinson's disease.

Moreover, the company has entered collaboration agreements with IGM Biosciences, Skyhawk Therapeutics, Amunix Pharmaceuticals, Scribe Therapeutics Inc., and Provention Bio, Inc., demonstrating its dedication to exploring cutting-edge technologies and treatment options in the healthcare sector.

Established in 1973 and headquartered in Paris, France, Sanofi was formerly known as Sanofi-Aventis and underwent a name change in May 2011. To learn more about Sanofi's products and initiatives, visit their official website at https://www.sanofi.com.

AI improved, may contain errors or wrong assumptions

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Sanofi ADR (SNY) - Stock Price & Dividends

SNY Stock Overview

Market Cap in USD 116,129m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 2002-07-01

SNY Stock Ratings

Fundamental 3.96
Dividend 6.90
Growth 5y 3.73
Rel. Performance vs Sector -0.98
Analysts 4.33
Fair Price Total Ret. 50.99
Fair Price DCF 1.75

SNY Dividends

Yield 12m 3.96%
Yield on Cost 5y 5.41%
Dividends CAGR 5y 1.79%
Payout Consistency 97.0%

SNY Growth Ratios

Growth 12m 6.08%
Growth Correlation 12m -13%
Growth Correlation 3m 4%
CAGR 5y 6.45%
CAGR / Mean Drawdown 0.84
Sharpe Ratio 12m 0.03
Alpha vs SP500 12m -14.38
Beta vs SP500 5y weekly 0.61
CAPM 6.91%
Average Daily Range 2m 1.30%
Regime Oscillator 53.01
Volatility GJR Garch 1y 22.51%
Price / SMA 50 -2.28%
Price / SMA 200 -5.64%
Current Volume 1347.3k
Average Volume 20d 2167k

External Links for SNY Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
X (Twitter)Stocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of SNY stocks?
As of February 29, 2024, the stock is trading at USD 48.00 with a total of 1,347,299 shares traded.
Over the past week, the price has changed by +0.17%, over one month by -4.53%, over three months by +2.17% and over the past year by +4.24%.
Why is SNY stock down?
Check with which Index or Commodity SNY has the highest Correlation, do they have a common driver?
Review the Fundamentals to find weaknesses (Debt, low returns). Check the Performance of the Peer-Group to find out, if the entire sector is under pressure.
Period Return SNY Return S&P 500
1 Month -4.53% 3.05%
3 Months 2.17% 11.73%
12 Months 4.24% 29.22%
What is the forecast for SNY stock price target?
According to ValueRays Forecast Model, SNY Sanofi ADR will be worth about 55.9 in February 2025. The stock is currently trading at 48.00. This means that the stock has a potential upside of +16.46%.
Issuer Forecast Upside
Wallstreet Target Price 59.3 23.6%
Analysts Target Price 65.1 35.7%
ValueRay Target Price 55.9 16.5%

Sanofi ADR: A Comprehensive Overview

History of Sanofi ADR

Sanofi ADR, part of the global healthcare leader Sanofi, has a rich history dating back to its establishment. It emerged from a series of mergers and acquisitions, most notably the union of Sanofi-Synthélabo and Aventis in 2004, forming one of the world's foremost pharmaceutical giants. Based in France, Sanofi has expanded its operations globally, establishing a strong presence in both developed and emerging markets.

Core Business

At its core, Sanofi is dedicated to improving health outcomes by developing, manufacturing, and marketing pharmaceutical drugs and vaccines. Its product portfolio includes a wide range of medications for conditions such as diabetes, rare diseases, multiple sclerosis, and oncology. Sanofi also possesses a significant footprint in the consumer healthcare sector, offering over-the-counter (OTC) medications that address everyday health concerns.

Side Businesses and Diversification

Beyond its primary pharmaceutical operations, Sanofi has diversified its business. This includes its investments in biotechnology and its venture into digital health solutions. Additionally, Sanofi's Genzyme division focuses on rare diseases and rare blood disorders, setting the company apart in highly specialized areas of medicine. The company has also been proactive in forging partnerships and collaborations that further its research capabilities and expand its market reach.

Current Market Status

Currently, Sanofi ADR (NASDAQ:SNY) remains a strong player in the pharmaceutical industry. It has demonstrated resilience and adaptability in a rapidly evolving market, often marked by increasing regulatory pressures and intense competition. With its strategic focus on innovation, especially in biotech and digital health, Sanofi aims to position itself at the forefront of healthcare advancements. Financially, it continues to exhibit robust performance, with steady revenue growth and a promising pipeline of future products.